DISIDA kinetics measure liver function in dogs

Ia, Fraser; Shaffer, Phillip; Ae, Staubus; Tuttle, Steven E.; Lc, Carey; Ec, Ellison

doi:10.1097/00006231-198906000-00010

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, hepatic uptake of 99m Tc-mebrofenin has proven resistant to high bilirubin levels [139,143], which is another reason why this is the most popular tracer in hepatobiliary scintigraphy, although it should be considered that, since albumin is the main plasma carrier of 99m Tc-mebrofenin, the liver uptake can be hindered in patients with hypoalbuminemia [140]. Prior to the establishment of 99m Tc-mebrofenin and 99m Tc-etifenin, various IDA derivatives have been developed as potential hepatobiliary CA, including DISIDA (disofenin [146,147,148,149,150]), HIDA (lidofenin) [139], PIPIDA [143], IOTIDA [151], diethylmonoiodo-IDA [152], as well as IDAs conjugated to phthalein and fluorescein moieties [153], to name only a few [139].…”

Section: Metal Complexes In Scintigraphic Liver Imagingmentioning

confidence: 99%

Metal-Based Complexes as Pharmaceuticals for Molecular Imaging of the Liver

2019

View full text Add to dashboard Cite

This article reviews the use of metal complexes as contrast agents (CA) and radiopharmaceuticals for the anatomical and functional imaging of the liver. The main focus was on two established imaging modalities: magnetic resonance imaging (MRI) and nuclear medicine, the latter including scintigraphy and positron emission tomography (PET). The review provides an overview on approved pharmaceuticals like Gd-based CA and 99mTc-based radiometal complexes, and also on novel agents such as 68Ga-based PET tracers. Metal complexes are presented by their imaging modality, with subsections focusing on their structure and mode of action. Uptake mechanisms, metabolism, and specificity are presented, in context with advantages and limitations of the diagnostic application and taking into account the respective imaging technique.

show abstract

Section: Metal Complexes In Scintigraphic Liver Imagingmentioning

confidence: 99%

Metal-Based Complexes as Pharmaceuticals for Molecular Imaging of the Liver

2019

View full text Add to dashboard Cite

show abstract

MR imaging assessment of experimental hepatic dysfunction with mn‐DPDP

Coley

Mattrey

Baker

et al. 1995

Magnetic Resonance Imaging

View full text Add to dashboard Cite

Manganese (II) N,N'-dipyridoxylethylenediamine-N,N'-diacetate 5,5'-bis(phosphate) (DPDP) is a paramagnetic magnetic resonance (MR) contrast agent that enhances the liver and is predominantly excreted through the biliary tree. The authors evaluated its utility in diffuse liver disease by assessing liver and gallbladder enhancement in 24 rabbits. Total (n = 6) or segmental (n = 6) biliary occlusion or galactosamine-induced hepatitis (n = 6) was induced 3 days before imaging. Six rabbits served as normal controls. T1- and T2-weighted axial MR images were acquired at baseline, followed by T1-weighted images every 10 minutes for 1 hour after the intravenous administration of 20 mumol/kg Mn-DPDP. Except for the segmental occlusion group, the baseline study did not allow distinction between normal and abnormal livers. The temporal hepatic enhancement pattern was statistically different for each group. The normal, segmental occlusion, and hepatitis groups showed patterns similar to one another but markedly higher signal intensity than the total-occlusion group throughout the observation period. In contrast, the gallbladder showed a greater difference in both degree of enhancement and time to peak enhancement among the four groups. Mn-DPDP produces a temporal hepatic enhancement pattern that allows recognition of markedly impaired livers, and gallbladder enhancement patterns that allow distinction of more subtly impaired livers.

show abstract

DISIDA kinetics measure liver function in dogs

Cited by 2 publications

References 0 publications

Metal-Based Complexes as Pharmaceuticals for Molecular Imaging of the Liver

Metal-Based Complexes as Pharmaceuticals for Molecular Imaging of the Liver

MR imaging assessment of experimental hepatic dysfunction with mn‐DPDP

Contact Info

Product

Resources

About